Jingwei Shida Completes Series B Financing to Advance Clinical Adoption of Confocal Microendoscopy for Early Cancer Diagnosis

Viestar Has Recently Completed Its Series B Financing Round. The Series B Investors Primarily Include Government Funds, Industrial Capital, and Prominent Social Capital from Multiple Regions, Such as Quanzhou (Fujian), Suzhou (Jiangsu), Wuhan (Hubei), Jinjiang (Fujian), and Wuxi (Jiangsu).

With the full support of its investors, viestar will further promote the clinical adoption of confocal laser endomicroscopy products, continue to focus on the precise diagnosis and efficient treatment of early-stage tumors, strategically develop innovative medical device products, and deploy comprehensive solutions tailored to specific application scenarios.

As the lead entity for national-level major scientific and technological initiatives and a key participant in advancing national medical strategic planning, viestar remains steadfast in its mission to continuously innovate for better quality of life. Centered on the goals of improving treatment outcomes for cancer patients and reducing healthcare expenditures, viestar collaborates closely with numerous authoritative medical and research institutions across China. Committed to becoming a core force in innovative cancer diagnosis and therapy, viestar leverages technological innovation to benefit human health and well-being.

Viestar has consistently maintained its industry-leading position in the field of confocal laser endomicroscopy by adhering to national policies and clinical needs, and leveraging its continuous technological innovation, superior supply chain integration, and robust large-scale manufacturing capabilities.

Viestar has been deeply committed to the niche field of confocal laser endomicroscopy for two decades.

Supported by the National Key R&D Program of China during the 13th Five-Year Plan period, we have overcome multiple technical challenges and established key production capabilities, achieving continuous breakthroughs in confocal microendoscopy in China—from initial development to international leadership.

During the 14th Five-Year Plan period, the confocal microendoscopy project led by viestar was selected for the National Key R&D Program of China. The company has continuously intensified its efforts to localize the core components of confocal microendoscopes, assisting technical and clinical experts in establishing Chinese standards by leveraging China’s industrial chain and technological advantages.

This round of financing marks another phase of strategic capacity-building for viestar. Leveraging capital support and its own organic growth, viestar will continue to invest in the research and development of key technologies, further expand the scale of confocal microscopy mass production, solidify its market leadership, and make significant contributions to the commercialization of confocal technology worldwide.